IBA sells new cyclotron to German neuroscience institute
Ion Beam Applications (IBA) has sold a new version of its Cyclone 30 to the Institute of Neurosciences and Medicine, INM-5: Nuclear Chemistry, a department of the Forschungszentrum Jülich in Jülich, Germany.
The Institute develops and produces radioactive labeled tracers for diagnostics of brain diseases, among others Parkinson’s disease, Alzheimer’s disease, epilepsy and brain tumors, using PET and PET/MRT (a combination of PET and MR Tomography).
The Cyclotron (Cyclotron C30XP) is a triple particles machine will be able to accelerate protons (at 30 MeV – millions electron volts), deuterons (at 15 MeV) and alpha particles (at 30 MeV), according to the Louvain-la-Neuve, Belgium-based IBA. The cyclotron will be operational in 2011 and used for research, teaching and development of next- generation radionuclides for new perspectives in the field of brain studies and cancer diagnosis and therapy.
The multi-particles accelerator opens the feasibility to produce short-lived PET radioisotopes, along with longer-lived emerging nonstandard PET-radioisotopes, and radioisotopes needed for medical diagnostics with SPECT, as well as for medical therapy of cancer—especially alpha particle emitters, such as the At-211 (astatine).
The Institute develops and produces radioactive labeled tracers for diagnostics of brain diseases, among others Parkinson’s disease, Alzheimer’s disease, epilepsy and brain tumors, using PET and PET/MRT (a combination of PET and MR Tomography).
The Cyclotron (Cyclotron C30XP) is a triple particles machine will be able to accelerate protons (at 30 MeV – millions electron volts), deuterons (at 15 MeV) and alpha particles (at 30 MeV), according to the Louvain-la-Neuve, Belgium-based IBA. The cyclotron will be operational in 2011 and used for research, teaching and development of next- generation radionuclides for new perspectives in the field of brain studies and cancer diagnosis and therapy.
The multi-particles accelerator opens the feasibility to produce short-lived PET radioisotopes, along with longer-lived emerging nonstandard PET-radioisotopes, and radioisotopes needed for medical diagnostics with SPECT, as well as for medical therapy of cancer—especially alpha particle emitters, such as the At-211 (astatine).